Tarsus Pharmaceuticals completes acquisition of Alkeus for retinal disease treatment
News provided byTarsus Pharmaceuticals Inc · 2 min read
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has successfully completed its acquisition of Alkeus Pharmaceuticals, Inc., a privately held biotech company specializing in retinal diseases. The deal adds ALK-001, a novel, Phase 3 investigational medicine, to Tarsus's pipeline, marking a significant step in the company's mission to become a leading player in the eye care sector.
ALK-001, also known as gildeuretinol acetate, is designed to address the underlying biology of Stargardt’s disease, a potentially blinding condition with no currently approved therapies. The medicine has received multiple FDA designations, including Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease, for Stargardt disease. It is currently in the global NORTHSTAR Phase 3 trial, with expected topline data in 2029.
“Completing the acquisition of Alkeus is a critical move for us as we aim to build a leading eye care company,” said Dr. Bobby Azamian, CEO and Chairman of Tarsus. “ALK-001 is a highly complementary addition to our pipeline, and it holds significant potential as a foundational medicine for individuals with Stargardt disease.”
Stargardt disease is a rare, inherited, and progressive condition that primarily affects the macula, the central part of the retina responsible for detailed vision. It often manifests in childhood or early adulthood and can severely impact a person's ability to read, recognize faces, drive, and perform daily tasks independently. The disease is estimated to affect around 86,000 people in the United States, with over 36,000 having been clinically diagnosed.
ALK-001 works by targeting toxic vitamin A dimerization in the retina, a key factor in the disease's progression. The medication has shown promising tolerability and efficacy in clinical studies involving over 400 participants.
The acquisition was announced on August 6, 2026, and closed after the satisfaction of customary closing conditions. Tarsus is now focused on advancing the ongoing NORTHSTAR trial and leveraging the drug’s potential.
In addition to its eye care portfolio, Tarsus is also developing other therapies in dermatology and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is currently approved for the treatment of Demodex blepharitis in the United States. The company is also advancing TP-04 for potential ocular rosacea treatment and TP-05 as an oral tablet for Lyme disease prevention, both in Phase 2, as well as IRX-101 for use as an ocular antiseptic.
Forward-looking statements in the press release caution that actual results may differ due to various risk factors, including the potential for the acquisition to fail to produce expected benefits. Tarsus advises readers not to rely on these statements and cautions that the company has no obligation to update them unless required by law.
With the addition of ALK-001, Tarsus is well positioned to address a significant unmet need in the eye care market, potentially offering a life-changing therapy for those suffering from Stargardt disease.